scholarly journals From in-silico immunogenicity verification to in vitro expression of recombinant Core-NS3 fusion protein of HCV

2017 ◽  
Vol 118 (04) ◽  
pp. 189-195 ◽  
Author(s):  
S. Hekmat ◽  
S. D. Siadat ◽  
M. R. Aghasadeghi ◽  
S. M. Sadat ◽  
G. Bahramali ◽  
...  
Keyword(s):  
Fusion Protein ◽  
In Silico ◽  
In Vitro Expression

In silico approach for designing a novel recombinant fusion protein as a Candidate Vaccine against HPV

2020 ◽  
Vol 17 ◽  
Author(s):  
Mohsen Sisakht ◽  
Amir Mahmoodzadeh ◽  
Mohammadsaeid Zahedi ◽  
Davood Rostamzadeh ◽  
Amin Moradi Hasan-Abad ◽  
...  
Keyword(s):  
Immune Responses ◽  
Fusion Protein ◽  
In Silico ◽  
Precancerous Lesions ◽  
Candidate Vaccine ◽  
T Cell Epitopes ◽  
Binding Interaction ◽  
Hpv16 E6 ◽  
E7 Proteins

Background: Human papillomavirus (HPV) is the main biological agent causing sexually transmitted diseases (STDs), including precancerous lesions and several types of prevalent cancers. To date, numerous types of vaccines are designed to prevent high-risk HPV. However, their prophylactic effect is not the same and does not clear previous infections. Therefore, there is an urgent need for developing therapeutic vaccines that trigger cell-mediated immune responses for the treatment of HPV. The HPV16 E6 and E7 proteins are ideal targets for vaccine therapy against HPV. Fusion protein vaccines, which include both immunogenic interest protein and an adjuvant for augmenting the immunogenicity effects, are theoretically capable of guarantee the power of the immune system against HPV. Method: A vaccine construct, including HPV16 E6/E7 proteins along with a heat shock protein GP96 (E6/E7-NTGP96 construct), was designed using in silico methods. By the aid of the SWISS-MODEL server, the optimal 3D model of the designed vaccine was selected, followed by physicochemical and molecular parameters were performed using bioinformatics tools. Docking studies were done to evaluate the binding interaction of the vaccine. Allergenicity, immunogenicity, B, and T cell epitopes of the designed construct were predicted. Results: Immunological and structural computational results illustrated that our designed construct is potentially proper for stimulation of cellular and humoral immune responses against HPV. Conclusion: Computational studies showed that the E6/E7-NTGP96 construct is a promising candidate vaccine that needs further in vitro and in vivo evaluations.

scholarly journals In silico design and in vitro expression of novel multiepitope DNA constructs based on HIV-1 proteins and Hsp70 T-cell epitopes

2021 ◽  
Author(s):  
Elahe Akbari ◽  
Kimia Kardani ◽  
Ali Namvar ◽  
Soheila Ajdary ◽  
Esmat Mirabzadeh Ardakani ◽  
...  
Keyword(s):  
T Cell ◽  
In Silico ◽  
T Cell Epitopes ◽  
In Vitro Expression ◽  
In Silico Design ◽  
Hiv 1

scholarly journals In Silico Drug Discovery of 4-Hyroxypanduratin A, 6-Gingerol and Luteolin Targeting Nipah Virus

2021 ◽  
pp. 477-484
Author(s):  
Anurag Verma ◽  
Piyush Mittal ◽  
Milind S. Pande ◽  
Neelanchal Trivedi
Keyword(s):  
Fusion Protein ◽  
In Silico ◽  
Virus Entry ◽  
Nipah Virus ◽  
Binding Energies ◽  
Viral Agent ◽  
In Silico Studies ◽  
Viral Target ◽  
Dietary Food

Nipah Virus is a zoo tonic virus and has re-emerged again with more deadliness. NiV has infected many animals and humans worldwide and a huge loss to life has been faced. NiV contains a Fusion protein on its outer membrane which helps in the virus entry into the host cell. This fusion protein is a virulent factor and is a major anti-viral target. Many medicinal plants have been used against viral diseases, current research aims towards the potential of three daily dietary food elements that can be used as an anti-viral agent. In-silico studies are performed with 4-hyroxypanduratin A, 6-gingerol and Luteolin against the NiV-F and binding energies were calculated. It was reported that these phyto-compounds have good negative binding energies and they have the promising potential against Nipah Virus. Further in-vitro research can be performed with these phyto-compounds to design a specific drug against Nipah Virus.

scholarly journals Synthesis, In Vitro, In Vivo and In Silico Antidiabetic Bioassays of 4-Niztro(thio)phenoxyisobutyric Acids Acting as Unexpected PPARγ Modulators: An In Combo Study

2022 ◽  
Vol 15 (1) ◽  
pp. 102
Author(s):  
Blanca Colin-Lozano ◽  
Héctor Torres-Gomez ◽  
Sergio Hidalgo-Figueroa ◽  
Fabiola Chávez-Silva ◽  
Samuel Estrada-Soto ◽  
...  
Keyword(s):  
Molecular Dynamics ◽  
Spectral Analysis ◽  
In Silico ◽  
In Vivo Studies ◽  
In Vitro Expression ◽  
Modes Of Action ◽  
In Vivo Effects ◽  
Orally Active

Four isobutyric acids (two nitro and two acetamido derivatives) were prepared in two steps and characterized using spectral analysis. The mRNA concentrations of PPARγ and GLUT-4 (two proteins documented as key diabetes targets) were increased by 3T3-L1 adipocytes treated with compounds 1–4, but an absence of in vitro expression of PPARα was observed. Docking and molecular dynamics studies revealed the plausible interaction between the synthesized compounds and PPARγ. In vivo studies established that compounds 1–4 have antihyperglycemic modes of action associated with insulin sensitization. Nitrocompound 2 was the most promising of the series, being orally active, and one of multiple modes of action could be selective PPARγ modulation due to its extra anchoring with Gln-286. In conclusion, we demonstrated that nitrocompound 2 showed strong in vitro and in vivo effects and can be considered as an experimental antidiabetic candidate.

In silico and in vitro screening of small molecule Inhibitors against SYT-SSX1 fusion protein in synovial sarcoma

2018 ◽  
Vol 77 ◽  
pp. 36-43
Author(s):  
Valliyammai Natarajan ◽  
Priya Ramanathan ◽  
Gopal Gopisetty ◽  
Balaji Ramachandran ◽  
Rajkumar Thangarajan ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Synovial Sarcoma ◽  
Small Molecule ◽  
In Silico ◽  
Small Molecule Inhibitors ◽  
In Vitro Screening

scholarly journals In Silico and In Vitro Investigations On Mutated IFNβ-scFv Against Human Collagen Type II

2021 ◽  
Author(s):  
Fatemeh Alimohammadi ◽  
Zohreh Hojati ◽  
Mazdak Ganjalikhani-Hakemi
Keyword(s):  
Fusion Protein ◽  
In Silico ◽  
Collagen Type ◽  
Hek293 Cells ◽  
Type Ii ◽  
Collagen Type Ii ◽  
Human Collagen ◽  
Clinical Experiments

Abstract Current medications for rheumatoid arthritis (RA), a common synovial autoimmune disease, are associated with adverse effects. Interestingly, interferon beta (IFNβ), effective in multiple sclerosis (MS) treatment, also can help decreasing articular destruction in RA. Here, a novel fusion protein was introduced containing human mutated IFNβ (with mutations in 27th and 101th residues; IFNβ27+101) fused to a single chain fragment variable (scFv) antibody against human collagen type II for decreasing IFNβ27+101 off-targets (according to drug targeting benefits) in future in vivo and clinical experiments. After designing, bioinformatic analyses and the recombinant vector transfection into HEK293 cells, the mutated IFNβ-scFv protein confirmation and function were assessed by SDS-PAGE, western blotting, ELISA, and real-time PCR. The fusion protein secondary and tertiary structures had proper folding. Also, the recombinant mRNA secondary structure considered stable. 2.35 fold difference between the test and negative control groups confirmed the scFv attachment to human collagen type II (p= 0.046). MxA 25.68 fold overexpression in peripheral blood mononuclear cells (PBMCs) treated with the recombinant protein compared with the non-treated sample (p= 0.0001), demonstrated IFNβ27+101 bioactivity as the fusion protein. In vitro and in silico studies verified function of mutated IFNβ-scFv, however in vivo studies are proposed for further validation.

Sign in / Sign up

Export Citation Format

Share Document